High-dimensional phenotyping in tissue inflammation:

       A major and growing focus of the lab is to gain novel insights into human disease processes via high-dimensional phenotyping of disease lesions. To do this, we have employed technologies aimed at maximizing the amount of information gleaned from precious clinical samples at the scale of cellular phenotype (CyTOF, scRNA-, CITE-, and immune repertoire-sequencing) or tissue organization (MICSSS, MIBI) in tissues, and pairing such data with multiplexed measurement of factors related to systemic immune response (o-link multiplex seromics).

       In developing such complex datasets for patient cohorts seen at Mount Sinai, we aim to identify biomarkers useful for refining treatment groups and pinpoint novel therapeutic targets. We are currently using such approaches in lab to investigate a number of disease categories, mainly autoimmune disease (IBD) and cancer (NSCLC, HCC, HNSCC, CRC). In order to correlate these data with response to immunotherapy, we are specifically integrating with a number of Phase I clinical trials in cancer. We believe that using high-dimensional readouts in early-phase trials can be important for identifying biological sub-groups displaying superior treatment response, as such information is crucial in subsequent trial design.